Company

Mithra Pharmaceuticals SA

Headquarters: Liège, Belgium

Employees: 300

FSX: 1TM

Market Cap

€80.3 Million

EUR as of Jan. 1, 2024

US$88.7 Million

Market Cap History

Mithra Pharmaceuticals SA market capitalization over time

Evolution of Mithra Pharmaceuticals SA market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Mithra Pharmaceuticals SA

Detailed Description

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for vasomotor menopausal symptoms relief; and PeriNesta, an oral treatment for perimenopause. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Mithra Pharmaceuticals SA has the following listings and related stock indices.


Stock: FSX: 1TM wb_incandescent

Stock: OTC: MITPF wb_incandescent

Details

Headquarters:

Rue Saint-Georges 5

Liège, 4000

Belgium

Phone: 32 4 349 28 22

Fax: 32 4 349 28 21